Scientists at the University of Freiburg have shown that antibody-based prophylactic treatment after bone marrow transplant (BMT) could prevent infections without reducing the diversity of the gut microbiome. BMT is a cure for a number of blood cancers, but it has a very high complication and death rate itself.